Prostate cancer
Results
Phase 1
This study looked at a drug called EZN 4176 for prostate cancer that has spread to another part of the body and is no longer responding to hormone therapy.
Doctors often use hormone therapy to treat prostate cancer. This can keep it under control for long periods of time. But researchers are looking for treatments that will help men who have prostate cancer that stops responding to hormone therapy.
Prostate cancer needs the hormone testosterone to grow. The cancer cells have receptors that the testosterone can lock into. This encourages the cancer cells to grow.
In this study, the researchers looked at a drug called EZN 4176. It stops cancer cells from making more receptors and so doctors hoped it would help to slow cancer growth.
The aims of this study were to
Find the highest safe dose of EZN 4176
See if it slows the growth of prostate cancer that is no longer responding to hormone therapy
Learn more about the side effects
Recruitment start: 1 April 2011
Recruitment end: 30 November 2012
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Prof Johann de Bono
Enzon Pharmaceuticals Inc
Last reviewed: 17 May 2015
CRUK internal database number: 9344